Fused quinoxaline derivatives as inhibitors of Akt activity

Details for Australian Patent Application No. 2003226271 (hide)

Owner Merck & Co., Inc.

Inventors Zhao, Zhijian; Lindsley, Craig W

Agent Spruson & Ferguson

Pub. Number AU-B-2003226271

PCT Number PCT/US03/10447

PCT Pub. Number WO2003/086404

Priority 60/417,411 09.10.02 US; 60/370,833 08.04.02 US

Filing date 4 April 2003

Wipo publication date 27 October 2003

Acceptance publication date 18 October 2007

International Classifications

A61K 31/498 (2006.01) - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine

A61K 31/4985 (2006.01) - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 35/00 (2006.01) Antineoplastic agents

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

C07D 519/00 (2006.01) Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

C07D 519/04 (2006.01) Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Event Publications

7 August 2003 Complete Application Filed

  Priority application(s): 60/417,411 09.10.02 US; 60/370,833 08.04.02 US

4 December 2003 Application Open to Public Inspection

  Published as AU-B-2003226271

18 October 2007 Application Accepted

  Published as AU-B-2003226271

14 February 2008 Standard Patent Sealed

21 January 2010 Amendment Made

  The nature of the amendment is: Amend patentee name from Merck & Co., Inc. to Merck Sharp & Dohme Corp.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003226272-A NOVEL G PROTEIN-COUPLED PURINERGIC RECEPTOR, GAVE 17

2003226270-Waste water treatment process for animal processing contaminant removal